Guillain-Barré Syndrome
9
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome
International Guillain-Barré Syndrome Outcome Study
A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome